2022 CSCO | Professor Wang Tao: Explore and forge ahead, and help patients with breast cancer brain metastases live longer and better lives

preface

The 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held
from November 5th to 12th.
The conference focuses on the clinical frontier of oncology, invites well-known experts and scholars at home and abroad to make wonderful progress reports or lectures, and strives to comprehensively and accurately reflect new concepts and new trends
in the field of clinical oncology.
On the occasion of this meeting, Yimaitong specially invited Professor Wang Tao, head of the fourth ward of the Department of Medical Oncology of the Fifth Medical Center of the PLA General Hospital, to share the current situation
of diagnosis and treatment of breast cancer brain metastasis.

Expert profiles

Professor Wang Tao

• Doctor of Medicine, Chief Physician, Professor, Master Supervisor

• Head of the fourth ward of the Department of Medical Oncology of the Fifth Medical Center of the PLA General Hospital

• Vice Chairman of the CSCO Neurological Oncology Committee

• Member of the CSCO Breast Disease Expert Committee

• Vice Chairman of the Youth Committee of Beijing Breast Disease Prevention and Control Society

• Member of the Standing Committee of the Breast Disease Professional Committee of the Chinese Anti-Cancer Association

"CSCO Breast Cancer Brain Metastasis Clinical Diagnosis and Treatment Expert Consensus" has been published in the journal Translational Breast Cancer Research (TBCR) on July 30
.
Could you please briefly introduce what this consensus covers? And what is the significance of its release?

Professor Wang Tao

The "Expert Consensus on the Clinical Diagnosis and Treatment of CSCO Breast Cancer Brain Metastasis" was completed under the guidance and leadership of Professor Jiang Zefei and the joint efforts of all members of CSCO BC, and was successfully published in TBCR.

The publication of consensus is of great
significance to guide the diagnosis and treatment of breast cancer brain metastasis.
At present, the global incidence of breast cancer has surpassed that of lung cancer, becoming the highest incidence of malignant tumors
in the world.
For breast cancer patients, even after receiving standard preoperative and postoperative treatment, 30%-40% of patients will eventually develop advanced breast cancer
.
Overall, as the treatment effect is getting better and better, the survival of patients with advanced breast cancer has been significantly prolonged
.
But at the same time, with the prolongation of patient survival, more opportunities for tumor cells to enter the brain are provided, and more and more brain metastases are found
clinically.
As we all know, due to the existence of the blood-brain barrier, many drugs can not enter the brain, or even if they can enter the brain, but the concentration of drugs in the brain is far lower than the concentration in the blood circulation, so that the efficacy is not good, at present, in clinical practice, the diagnosis and treatment of brain metastases is still the focus and
difficulty.

The "CSCO Expert Consensus on Clinical Diagnosis and Treatment of Breast Cancer Brain Metastasis" covers the epidemiology, clinical manifestations, imaging diagnosis, pathological diagnosis, medical treatment, surgical treatment and other aspects
of breast cancer brain metastasis.
All parts of the consensus have invited authoritative experts and scholars in the field to write, giving the most professional opinions and suggestions, incorporating cutting-edge new drugs and the latest heavy research progress, which greatly improves the level and quality of consensus to better guide the diagnosis and treatment
of breast cancer brain metastasis.
In addition, the consensus also incorporates the content of follow-up, and explains in great detail
how to follow-up, monitor, and predict.

Overall, the content of the "CSCO Expert Consensus on Clinical Diagnosis and Treatment of Breast Cancer Brain Metastasis" is very comprehensive
.
Due to the English page requirements of TBCR journals, the original Chinese edition was partially deleted at the time of publication, and the essence of consensus has been published in TBCR.

We also look forward to the publication of a more comprehensive Chinese version of the consensus in the near future
.

Yimaitong: Breast cancer treatment has ushered in the era of classified treatment according to molecular typing, what points should be paid attention to in the treatment of different types of breast cancer brain metastases?

Professor Wang Tao

Different types of breast cancer have different times, methods, severity, and prognosis of brain metastases
.
Breast cancer has long entered the era
of molecular typing and classification therapy.
From an epidemiological point of view, triple-negative breast cancer brain metastases occur earlier, have a worse prognosis, and have a shorter overall survival time.
Patients with HR-positive brain metastases generally develop brain metastases in the terminal stage, and overall, the incidence is not too high; The occurrence of brain metastases in patients with HER2-positive breast cancer is gradually accumulated over time
.
In terms of treatment, the most fortunate is HER2-positive breast cancer patients, in addition to local treatment methods such as surgery and radiotherapy, there are currently new drugs including small molecule TKI, large molecule ADC and other new drugs can show good therapeutic effects
.
In addition, in the mode of administration, in addition to intravenous administration, the intrathecal injection of anti-HER2 drugs also showed good results
.
I hope that under the leadership of the CSCO BC Special Committee, we can do more clinical research to explore more new methods and technologies for the treatment of breast cancer brain metastasis, so that the survival of brain metastasis patients can be better prolonged
.

Editor: Uni

Reviewer: Professor Wang Tao

Typesetting: Uni

Execution: Yuna

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.